First Horizon Advisors, Inc. Trevi Therapeutics, Inc. Call Options Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TRVI
# of Institutions
152Shares Held
85.5MCall Options Held
1.51MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$82.1 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$74.1 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$32.8 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$27.7 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$25.2 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $421M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...